Please check your internet connection and try again.
## Sompraz HP
### Overview
Sompraz HP is a combination medication containing vonoprazan, amoxicillin, and clarithromycin, used for the eradication of *Helicobacter pylori*. Vonoprazan is a potassium-competitive acid blocker (P-CAB), while amoxicillin and clarithromycin are antibiotics.
### Primary Indications
* Eradication of *Helicobacter pylori* in patients with peptic ulcer disease or after successful eradication.
### Adult Dosing
* **Standard Regimen:** One kit orally twice daily for 14 days. Each kit contains:
* Vonoprazan 20 mg
* Amoxicillin 500 mg
* Clarithromycin 200 mg (or 250 mg, depending on formulation)
### Pediatric Dosing
* Dosing for Sompraz HP in pediatric populations is not established. Vonoprazan, amoxicillin, and clarithromycin individually have pediatric dosing, but specific combination guidelines for Sompraz HP are not available.
### Dose Adjustments
* **Renal Impairment:** No specific dose adjustment recommendations for Sompraz HP. Caution may be warranted in severe renal impairment.
* **Hepatic Impairment:** No specific dose adjustment recommendations for Sompraz HP. Caution may be warranted in severe hepatic impairment.
### Contraindications
* Hypersensitivity to vonoprazan, amoxicillin, clarithromycin, or any component of the formulation.
* History of cholestatic jaundice or hepatic dysfunction associated with prior clarithromycin use.
* Congenital QT prolongation, known QT interval prolongation, electrolyte imbalance, or concurrent use of other medications known to prolong the QT interval (e.g., certain antiarrhythmics, antipsychotics, antidepressants).
* Severe renal impairment or severe hepatic impairment (relative contraindication, use with caution).
* History of penicillin allergy.
### Adverse Effects
* **Common:** Diarrhea, abdominal pain, nausea, vomiting, rash, altered taste, headache.
* **Serious:** *Clostridioides difficile*-associated diarrhea, hypersensitivity reactions (including anaphylaxis), QT prolongation, hepatotoxicity, Stevens-Johnson syndrome/toxic epidermal necrolysis, blood dyscrasias (rare).
### Key Drug Interactions
* **CYP3A4 Inhibitors/Inducers:** Clarithromycin is a moderate CYP3A4 inhibitor. May increase concentrations of drugs metabolized by CYP3A4 (e.g., statins, warfarin, benzodiazepines, calcium channel blockers). Vonoprazan is metabolized by CYP3A4 and UGT1A1; coadministration with strong CYP3A4 inducers may decrease its efficacy.
* **QT Prolonging Agents:** Concomitant use with other drugs known to prolong the QT interval can increase the risk of arrhythmias.
* **Penicillin-Degrading Bacteria:** Amoxicillin may be inactivated by beta-lactamases.
* **Proton Pump Inhibitors (PPIs) / Other Acid Reducers:** Vonoprazan's effect on gastric acid suppression may alter absorption of drugs dependent on gastric pH.
### Monitoring
* Signs and symptoms of *H. pylori* eradication (e.g., urea breath test, stool antigen test, or biopsy-based testing at least 4 weeks after completion of therapy).
* Signs of hypersensitivity reactions.
* Signs of liver dysfunction (e.g., jaundice, elevated transaminases).
* Electrolyte abnormalities and signs of QT prolongation, especially in patients with risk factors.
* Signs and symptoms of *C. difficile* infection.
### Clinical Pearls
* This is a 14-day regimen. Ensure patient compliance for optimal eradication rates.
* Dosing may need to be adjusted based on local resistance patterns for *H. pylori*.
* Advise patients to take the medication as prescribed and report any significant side effects immediately.
* Consider alternative regimens if a patient has a known penicillin allergy or clarithromycin resistance.
***
*This information is intended for healthcare professionals. Always verify the most current prescribing information and local guidelines before initiating therapy.*
